Clin Respir J. 2015 Apr;9(2):129-42. doi: 10.1111/crj.12134. Epub 2014 May 21.

Consensus statement on the management of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Asia.

Cao B(1), Tan TT, Poon E, Wang JT, Kumar S, Liam CH, Ahmed K, Moral P, Qiu H, Barez MY, Buntaran L, Tampubolon OE, Thamlikitkul V.

Author information: (1)Department of Infectious Diseases and Clinical Microbiology, Beijing Chaoyang Hospital, Capital Medical University Beijing, Beijing, China.

Nosocomial pneumonia (NP; encompassing hospital-acquired, health care-associated and ventilator-associated pneumonia) is one of the most common nosocomial infections and is associated with a mortality rate of 18.7%-40.8% in Asian countries. The burden of methicillin-resistant Staphylococcus aureus (MRSA) infections in Asia is high, and approximately 13% of NP cases in Asia are caused by this pathogen. Evidence regarding optimal management of MRSA NP continues to evolve and is complicated by the fact that a significant proportion of cases are likely to be caused by isolates with reduced susceptibility to the main therapeutic agent, vancomycin. The Asian Consensus Taskforce on MRSA Nosocomial Pneumonia has developed this statement to provide consensus points on diagnosis, antimicrobial treatment and prevention strategies for MRSA NP in the Asian context, based on our review of Asian data, previous international guidelines and recent scientific evidence.

© 2014 John Wiley & Sons Ltd. DOI: 10.1111/crj.12134

PMID: 24725393 [Indexed for MEDLINE]